Bio-Techne (TECH) cash flow statement

Life Sciences Tools & Services · NASDAQ · Health Care

$72.63 -0.22% Close Nov 17, 2026 Live

TrendArc score 46 of 100 · Health 5.9 · Momentum 7.0 · Moat 3.9 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to June 30, 2026

$263 million

up 2.6% from the year before

Bio-Techne generated $263 million of free cash flow in the fiscal year to June 2026: $292 million of cash from operations less $29 million of capital spending. That was 21.7% of revenue, against 21.0% the year before. Over the last four quarters, to September 30, 2026, it was $308 million.

What stands out

  • It paid cash dividends in each of the last ten fiscal years.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

$100M$200M$300M$400M2017201820192020202120222023202420252026$129MFree cash flow $263MNet income $182M$100M$200M$300M$400M20182020202220242026Free cash flow $263MNet income $182M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to June 30, 2026

  1. Cash from operations 292
  2. Capital spending -29
  3. Free cash flow 263
  4. Businesses bought and sold, net 11
  5. Net share issuance 39
  6. Dividends -50
  7. Debt and other -160
  8. Net change in cash 103

In millions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In millions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Jun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
Operating activities
Net income182731682852721402299612676
Depreciation and amortisation971101121071018883786460
Stock-based pay4341413839424932322815
Working capital and other items-2963-19-177-9075-139-25-48-7
Cash from operations338292288299254325352205182170144
Investing activities
Capital spending-29-29-31-63-38-45-44-52-25-21-15
Businesses bought and sold, net11-5-163-2420-2262-289-46-294
Investments bought and sold, net012315-522777-22283
Cash from investing-18-35-203-266-97-24427-337-39-306
Financing activities
Debt issued or repaid, net-14627-3194-86-16-149167-5252
Shares issued less bought back5239-224-1910-84222123195
Dividends paid-50-50-50-50-50-50-50-49-48-48-47
Other financing-12-7-22-31-23-19-7-6-66-21
Cash from financing-169-254-12223-243-63-184134-99189
Exchange rate effect-212-2-3-126-30-20
Net change in cash10310-298-275246-213027
Free cash flow
Free cash flow308263257236216280308153156149129
Free cash flow margin25.1%21.7%21.0%20.4%19.0%25.4%33.1%20.8%21.9%23.2%22.8%
Free cash flow per share$1.68$1.61$1.47$1.34$1.71$1.90$0.97$1.00$0.98$0.86
Free cash flow less stock-based pay222216198177238259121124121114

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Bio-Techne against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
Bio-TechneTECH Jun 2026$263M21.7%
IlluminaILMN Dec 2025$931M21.4%
Mettler ToledoMTD Dec 2025$849M21.1%
WatersWAT Dec 2025$543M17.1%
Agilent TechnologiesA Oct 2025$1.15B16.6%
IQVIAIQV Dec 2025$2.13B13.0%
Charles River LaboratoriesCRL Dec 2025$518M12.9%
Peer median16.9%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Bio-Techne with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Bio-Techne from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.